03.03.2005 22:31:00

LabOne Adds Lawrence N. Kugelman to Its Board of Directors

LabOne Adds Lawrence N. Kugelman to Its Board of Directors


    Business Editors

    LENEXA, Kan.--(BUSINESS WIRE)--March 3, 2005--LabOne, Inc. (Nasdaq: LABS) announced today that its board has appointed Lawrence N. Kugelman as a Class C director effective March 2, 2005. His term ends at the annual meeting of shareholders in May 2005, when shareholders will vote on his election to an additional three year term. Kugelman replaces W. Roger Drury who resigned from the board on February 26, 2005.
    Kugelman is a former president and chief executive officer of Coventry Health Care, a leading managed health care company. Prior to joining Coventry Health Care, he served in several leadership positions within the health care industry.
    Kugelman currently is a health care consultant and private investor. He is a director and chairman of the audit committee for Coventry Health Care and a director and chairman of the compensation committee for Valeant Pharmaceuticals International.
    Kugelman received a BA from St. John's University, an MBA from the Owen Graduate School of Management at Vanderbilt University, and an MA from the University of Ulster.

    About LabOne, Inc.

    Headquartered in the Greater Kansas City area, LabOne is a diagnostic services provider. The services and information LabOne and its subsidiaries provide include: risk assessment information services for the insurance industry; diagnostic health care testing to physicians, hospitals, managed care organizations and employers; and drug testing services and related employee qualification products to employers and the government. The company's web site is located at http://www.LabOne.com.

--30--PT/dx*

CONTACT: LabOne, Inc. John McCarty, 913-577-1244 john.mccarty@LabOne.com

KEYWORD: KANSAS INDUSTRY KEYWORD: INSURANCE PHARMACEUTICAL MEDICAL DEVICES MEDICAL MANAGEMENT CHANGES SOURCE: LabOne, Inc.

Copyright Business Wire 2005

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu LabOne Inc.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu LabOne Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

NASDAQ Comp. 19 392,61 -1,20%